Clinical trials: Active Rheumatoid Arthritis
Rheumatoid Arthritis
Exercise Perceptions and Preferences Among Rheumatoid Arthritis Patients
The purpose of the study is to analyse exercise behaviour of rheumatoid arthritis patients.
- Trial name
- NCT01596348
- Where
- Switzerland
- Volunteers
- 120 people
- Sponsor
- University of Lausanne
Rheumatoid Arthritis
TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.
- Trial name
- NCT04413617
- Testing
- PF-06650833, PF-06651600, Tofacitinib
- Where
- 144 sites in Bulgaria, Canada and 8 more
- Volunteers
- 460 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Phase IIIB Subcutaneous Missed Dose Study
The purpose of the study is to determine whether subcutaneous abatacept administered to patients with rheumatoid arthritis is associated with increased immunogenicity or increased safety events upon withdrawal and reintroduction.
- Trial name
- NCT00533897
- Testing
- Abatacept
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 270 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Rheumatoid Arthritis
Rheumatoid arthritis is an autoimmune disease characterized by synovial inflammation and joint destruction that follows a relapsing- remitting course.Disease activity assessment is important for rheumatoid arthritis management…
- Trial name
- NCT03617250
- Testing
- Disease Activity Score-28
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Rheumatoid Arthritis, Fibromyalgia, Secondary
Predictive Utility of a Short-term Improvement in Objectively Measured Physical Activity in Rheumatoid Arthritis (PUSIPA)
SUMMARY Background: Several studies have shown physical activity (PA) to be inversely correlated to disease activity in rheumatoid arthritis (RA) patients.
- Conditions
- Rheumatoid Arthritis, Fibromyalgia, Secondary, Fatigue, Physical Inactivity
- Trial name
- PUSIPA (NCT06289114)
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
Disease Activity
14.0- 3.0- 3.0- η Protein With Rheumatoid Arthritis
Aim of work: to explore the potential association between serum 14.0-3.0-3.0- η protein level with disease activity and bone mineral density (BMD) in Egyptian patients with rheumatoid arthritis (RA).
- Trial name
- NCT05366608
- Testing
- Serum level of 14.0- 3.0- 3.0- η protein and IL_.6
- Where
- Egypt
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Inflammatory Arthritis, Ankylosing Spondylitis
Impact of Barriers and Facilitators to Physical Activity in Patients With Inflammatory Arthritis
Background: Patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic arthritis (PsA) are more prone to physical inactivity but derive specific benefits from regular…
- Conditions
- Inflammatory Arthritis, Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis
- Trial name
- ImBAIA (NCT04426747)
- Testing
- No intervention
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Rheumatoid Arthritis
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the long-term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis (RA) who completed study RA0083 [NCT01463059].
- Trial name
- NCT01533714
- Testing
- CDP6038 (olokizumab)
- Where
- 32 sites in Japan, South Korea and 1 more
- Volunteers
- 103 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- REASSURE (NCT01377012)
- Testing
- Secukinumab (AIN457)
- Where
- 142 sites in United States, Argentina and 14 more
- Volunteers
- 637 people
- Sponsor
- Novartis Pharmaceuticals
Primary Sjogren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)
- Trial name
- UPSTREAM SjD (NCT07404865)
- Testing
- Telitacicept
- Where
- 49 sites in United States, Georgia
- Volunteers
- 250 people
- Sponsor
- Vor Biopharma
Rheumatoid Arthritis
An Animated Home-based Physical Exercise Program as a Treatment Option for Patients With Rheumatoid Arthritis
The purpose of this pilot study is to investigate feasibility and patients´ assessment using an animated home-based exercise program (Software Wii-fit of the Nintendo Wii game console) for patients with rheumatoid arthritis.
- Trial name
- NCT02658370
- Testing
- animated home-based exercises (Wii-fit), conventional home-based exercise program
- Volunteers
- 30 people
- Sponsor
- Eugen Feist
Rheumatoid Arthritis
REU-stop - Effect of Intensive Smoking Cessation Intervention on Smoking Cessation and Disease Activity in Patients With Rheumatoid Arthritis.
This study aims to test the effect of an intensive smoking cessation intervention (motivational counseling combined with nicotine replacement) on smoking cessation and disease activity in patients with Rheumatoid Arthritis (RA).
- Trial name
- NCT02901886
- Testing
- Intensive smoking cessation intervention
- Where
- 2 sites in Denmark, Norway
- Volunteers
- 150 people
- Sponsor
- Glostrup University Hospital, Copenhagen
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
This single arm study will evaluate the efficacy and safety of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response to one or more anti-TNF therapies.
- Trial name
- NCT00462345
- Testing
- rituximab, Methotrexate, Corticosteroid or NSAID
- Where
- 4 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Active Rheumatoid Arthritis
A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis
This study is ongoing to explore the efficacy and safety of different strengths of SHR-3045 injection in moderate to severe active rheumatoid arthritis.
- Trial name
- NCT07233655
- Testing
- SHR-3045 Injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Arthritis, Rheumatoid
Study Evaluating the Efficacy and Safety of Etanercept in Chinese Subjects With Rheumatoid Arthritis
The objective of this study is to compare in Chinese subjects with rheumatoid arthritis (RA) the efficacy and safety in this subject population of 50 mg once-weekly injections of etanercept versus placebo in subjects receiving…
- Trial name
- NCT00443950
- Testing
- Etanercept
- Where
- 6 sites in China
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate…
- Trial name
- NCT01235507
- Testing
- methotrexate, tocilizumab [RoActemra/Actemra]
- Where
- 3 sites in Bosnia and Herzegovina
- Volunteers
- 71 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis (RA)
"Matrix Metalloproteinases 7 and 9 in Rheumatoid Arthritis Patients With Interstitial Lung Disease"
This case control study will be done at Rheumatology Department, Assiut University Hospital. It will include RA patients fulfilling the American College of Rheumatology and European League against Rheumatism (ACR / EULAR) 2010…
- Trial name
- NCT07173582
- Testing
- Serum samples will be collected at the time of registry enrollment, MMP 7 and 9 concentrations will be measured using enzyme-linked immunosorbent assays.
- Where
- Egypt
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Assiut University
Rheumatoid Arthritis
Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept
The purpose of this study is to determine whether the blood levels of abatacept drug product manufactured using High Metals and using Low Metals are comparable in healthy subjects.
- Trial name
- NCT01221636
- Testing
- Abatacept
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
This is a Phase IIa/b double-blind, placebo-controlled, randomized, parallel group, multicenter study to evaluate the safety and efficacy of RO7123520 as adjunctive therapy in participants with RA who are inadequately responding…
- Trial name
- NCT03001219
- Testing
- Anti-TNF-alpha, Methotrexate, RO7123520
- Where
- 81 sites in United States, Argentina and 9 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Inflammation, Rheumatoid Arthritis
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis
This trial is conducted in Europe. The aim of the trial is to evaluate the change in disease activity following intravenous (i.v.) administration of two doses of NNC0114-0006 compared to placebo in subjects with active rheumatoid…
- Trial name
- NCT01647451
- Testing
- NNC0114-0006
- Where
- 33 sites in Bulgaria, Hungary and 5 more
- Volunteers
- 62 people
- Sponsor
- Novo Nordisk A/S